Cargando…
Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members
BACKGROUND: Due to the low mutational testing rate in patients with Gastrointestinal Stromal Tumors (GIST), The Life Raft Group (LRG), a non-profit organization that provides support, advocacy and conducts research for patients with GIST, analyzed various factors that may have an impact on patients’...
Autores principales: | Montoya, Denisse, Call, Jerry W., Eshak, Jennily, Knox, Pete, Luedke, Maeven, Kaur, Sahibjeet, Rothschild, Sara, Garland, Mary, Scherzer, Norman J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667594/ https://www.ncbi.nlm.nih.gov/pubmed/36380293 http://dx.doi.org/10.1186/s12876-022-02548-8 |
Ejemplares similares
-
Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
por: Call, Jerry W., et al.
Publicado: (2019) -
Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
por: Call, Jerry W., et al.
Publicado: (2019) -
Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry
por: Call, Jerry, et al.
Publicado: (2012) -
Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)
por: Hauber, A Brett, et al.
Publicado: (2011) -
The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005)